+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hemophilia: Epidemiology Forecast to 2028

  • ID: 4829190
  • Report
  • July 2019
  • Region: Global
  • 48 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Hemophilia: Epidemiology Forecast to 2028

Summary

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (Hemophilia A) or factor IX (Hemophilia B). Hemophilia is a rare, genetic, potentially life-threatening bleeding disorder. The clinical presentation of hemophilia ranges from mild, to moderate, to severe stages, depending on the residual level of the circulating factor.

The diagnosed prevalent cases of hemophilia in the US are likely to exceed that of China over the next decade, with 18,723 cases in the US in 2028 as compared to 14,186 cases in China in 2028, due to higher hemophilia knowledge in the US as compared to China.

Diagnosed prevalent cases of Hemophilia A and Hemophilia B is forecasts to increase across the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and China), from 67,051 cases in 2018 and 67,678 cases in 2028, at an Annual Growth Rate (AGR) of 0.09%. The US will have the highest number of diagnosed prevalent cases of hemophilia A and Hemophilia B among the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and China), while Spain will have the lowest.

Epidemiologists forecast an increase in the diagnosed prevalent cases of acquired hemophilia from 2,163 diagnosed prevalent cases in 2018 to 2,215 diagnosed prevalent cases in 2028, with an AGR of 0.24% during the forecast period. China will have the highest number of diagnosed prevalent cases of acquired hemophilia among the eight major markets, while Spain will have the lowest.

The latest report "Hemophilia: Epidemiology Forecast to 2028", reveals that the relatively stable trend in the diagnosed prevalent cases of hemophilia over the next decade is partly attributable to changing population demographics in the next ten years. The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and Hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B are further segmented by severity (mild, moderate, and severe), inhibitors status, inhibitors severity (high responding and low responding), and type of treatment (prophylaxis and on-demand). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acquired hemophilia.

Scope
  • The Hemophilia Epidemiology Report provides an overview of the risk factors and global trends of hemophilia in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B are further segmented by severity (mild, moderate, and severe), inhibitors status, inhibitors severity (high responding and low responding), and type of treatment (prophylaxis and on-demand). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acquired hemophilia.
  • The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy

The Hemophilia Epidemiology report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
  • Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
  • Understand magnitude of hemophilia population by severity.
Note: Product cover images may vary from those shown
2 of 2
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Hemophilia: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
3.4.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.4.7 Type of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.4.8 Diagnosed Prevalent Cases of Acquired Hemophilia
3.5 Epidemiological Forecast for Hemophilia A (2018-2028)
3.5.1 Diagnosed Prevalent Cases of Hemophilia A
3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
3.6 Epidemiological Forecast for Hemophilia B (2018-2028)
3.6.1 Diagnosed Prevalent Cases of Hemophilia B
3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
3.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2018-2028)
3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
3.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.7 Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
3.8 Discussion
3.8.1 Epidemiological Forecast Insight
3.8.2 Limitations of Analysis
3.8.3 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Author
4.4 Contact Us
4.5 Disclaimer

List of Tables
Table 1: Relationship of Bleeding Severity with Clotting Factor Level.
Table 2: Comorbidities for Hemophilia

List of Figures
Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2018 and 2028
Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, All Ages, 2018 and 2028
Figure 3: 8MM, Diagnosed Prevalence of Hemophilia A (%), All Ages, 2018
Figure 4: 8MM, Diagnosed Prevalence of Hemophilia B (%), All Ages, 2018
Figure 5: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 6: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity
Figure 7: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
Figure 8: 8MM, Sources Used, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 9: 8MM, Sources Used, Type of Treatment Among Hemophilia A and Hemophilia B Patients
Figure 10: 8MM, Sources Used, Diagnosed Prevalent Cases of Acquired Hemophilia
Figure 11: 8MM, Diagnosed Prevalent Cases of Hemophilia A, All Ages, Both Sexes, N, 2018
Figure 12: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, N, 2018
Figure 13: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, All Ages, N, 2018
Figure 14: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2018
Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia B, All Ages, Both Sexes, 2018
Figure 17: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, 2018
Figure 18: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, All Ages, N, 2018
Figure 19: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2018
Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018
Figure 22: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018
Figure 23: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2018
Figure 24: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2018
Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 26: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018
Figure 27: 8MM, Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018
Figure 28: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, All Ages, Both Sexes, N, 2018
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll